Post on 21-Apr-2018
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved1
Professor Arun SharmaUniversity of Miami
Compliance as a Strategic Function
©Arun Sharma, All Rights Reserved2
Goals ‐ Background
Compliance leaders need expertise in three areas: – Compliance expertise which incorporates skills such as risk management, policy development, regulatory knowledge, investigation and monitoring/auditing.• Compliance leaders have strong competencies in this area.
– Leadership expertise with skills associated with leading and motivating compliance teams. • Compliance leaders are beginning to develop deep expertise in this area.
– Strategic expertise and skills required to give flight to the business and elevate the role of the compliance function within pharmaceutical firms. • Focus of the Session.
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved3
Goals
Understand pharmaceutical global market trends and the role of multinational, regional and domestic firms in multiple markets.
Understand how compliance leaders can provide a strategic advantage to firms through innovations in compliance strategies that enhance business (within the tenets of an ethical policy)?Understand how compliance leaders can recognize the emerging changes in the environment and be the first‐to‐market with innovative compliance strategies?
Understand how multinational firms compete when their compliancepolicies do not match the policies of competitors? – How can compliance leaders better understand their customers and develop
innovative non‐duplicatable compliance strategies such as brand leveraging to help their firms grow rapidly in markets?
©Arun Sharma, All Rights Reserved4
Day One Day Two Day Three
Breakfast
Morning Session I
Understanding the Medical Devices Industry and Challenges in Global
Markets Moderator Presentation and
Discussion
Current Compliance Issues in Processes I
(Groups and Company Experts)
Presentation and Discussion
Enhancing the Compliance Function I (What can we do
to aid the Business?)
Moderator Presentation and Discussion
Break ‐ I
Morning Session II
Thinking Strategically About Compliance – SWOT and
Scenario Planning
Moderator Supervised Hands‐on Exercise
Current Compliance Issues in Processes II
(Groups and Company Experts)
Presentation and Discussion
Enhancing the Compliance Function II (What can we do
to aid the Business?)
Moderator Presentation and Discussion
Lunch
Afternoon Session I
Developing a Vision and Strategy for
Global/Regional Compliance
Moderated Group Discussion
Current Compliance Issues in Markets I
(Global/Regional/Country Leaders Present)
Presentation and Discussion
Applying Framework to Global, Regions and
Countries – Plans, Pilots, Outcomes and Timelines I
Moderated Workshop
Break II
Afternoon Session II
Creating a Vision and Strategy Document – Our focus; What will we do? What will we not do?
Moderated Group
Discussion
Current Compliance Issues in Markets II
(Global/Regional/Country Leaders Present)
Presentation and Discussion
Applying Framework to Global, Regions and
Countries – Plans, Pilots, Outcomes and Timelines II
Wrap up
Moderated Workshop
This Post‐Session is Based on a Compliance Strategy Programs That We have Conducted for Regional Global Compliance Over 50 Times
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved5
Layout – Section I
Why Grow?
The Pharma Industry.
Three Disruptors.– Generics
– Biologics
– Emerging Markets
Two Track Markets
©Arun Sharma, All Rights Reserved6
The Imperative for Growth (Examining Stalls)500 Fortune 100 and Global 100 Firms 1955‐2006
(S or N)26%
Percentage of Customers
Time
Moderate or High Growth
46%
Stalled87%
Later
Slow or Negative Growth 54%
13% Grew
No Longer Exist
67%
Moderate or High Growth 7%
Ten YearsLater
Source: Olson, Bever and Verry, “When Growth Stalls, HBR, March 2008
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved7
How do We Study Markets?
Understand Market Strategy Models.
What are the Fundamental Shifts in the Industry.– Change in Values.
Who are the Key Competitors?
Who are the Winners and Losers?
Is There is a Pending Crisis in the Industry?
What Are the Wild Cards?
Use Patterns to Predict Future.
©Arun Sharma, All Rights Reserved8
MARKET STRATEGY MODELS FOR THE PHARMACEUTICAL INDUSTRY
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved9
Pharmaceutical Markets
©Arun Sharma, All Rights Reserved10
Success of Pharmaceutical Firms
Helps More than Hurts (Barriers to Entry)
Helps/ Complicates (Barriers to Entry)
Non-price Competition
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved11
Sharma Model ‐‐ Industry Drivers
©Arun Sharma, All Rights Reserved12
Industry Shifts – Long Term
Stage IIIStage IIStage I
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved13
Market Leadership Model
13
Best of Class
Threshold Value
Customer Intimacy(Total Solution)
Operational Excellence(Total Cost)
Source: Michael Treacy and Fred Wiersema (1997)
Product Superiority(Innovation and Consumption Experience)
©Arun Sharma, All Rights Reserved14
Market Leadership Model Strategies
Operational Excellence
Product Leadership
Customer Intimacy
Key Deliverable •Best Total Cost •Best Product •Best Total SolutionCore Value •Efficiency •Continuous
Innovation•Client Solution Focus
Key Processes •Emphasis on Value Chain•Continuous Improvement
•Bring‐to‐Market Innovations•Cycle Time Reduction
•Customer Focus Strategies•Customer Expertise•Customization
Challenges •Market Shifts •Technology Shifts •Customer Shifts
Source: Adapted from Michael Treacy and Fred Wiersema (1997)
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved15
Looking for Growth
Customer/Market Match
Adjacent Similar
Product/Service Match
Adjacent
Similar
©Arun Sharma, All Rights Reserved16
THE PHARMACEUTICAL MARKET
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved17
Our Study of Industry and Trends
In 2013 more firms are missing their growth targets when compared to the last decade.
Concerns about the effectiveness of current market strategies have increased.
The Pharma business has nineteen Big Pharma firms and over 200 smaller firms.
– As long as reimbursements were high (gross margin for this industry was over 80%), there was little need for industry consolidation.
– The industry is under attack from the bottom (generic drugs) and the top (too many similar medicines).
– Emerging Market Firms are Growing.
©Arun Sharma, All Rights Reserved18
Industry Trends
2011 sales expected to be $900 Billion; 2015 ‐‐ $1 Trillion; 2020 ‐‐ $1.15 Trillion. – Slowest growth in 20 years.
– Emerging Markets will provide 75% of Growth in 2012‐2020.
Major Shifts in Developed Markets.– Reduction in Pricing in Developed Countries.
Generics have Grown in All markets.– Generics will be 85% of the Growth.
Innovation Cycle is Deeply Disrupted.– Some Developed Markets May Have negative Growth.
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved19
20th Century Model
Nineteen Big Pharma.– Model.
• Focus on Western Europe, USA and Japan.• Patent Protectable Drugs.
• Differential Pricing.– Lobbying for Price Protection.
• Strong Legal Barriers.– Regulation.
• Contain Spread of Emerging Nation Firms.
Small Emerging Nation Firms.– Focus on Emerging markets.
• Small Internal Markets.
©Arun Sharma, All Rights Reserved20
Examples of Pricing (2013)
Source: Elizabeth Robinson, The Soaring Cost of a Simple Breath, NY Times, October 13, 2013; http://www.nytimes.com/2013/10/13/us/the‐soaring‐cost‐of‐a‐simple‐breath.html?_r=0
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved21
Consequences of the 20th Century Model
None of the Nineteen Big Pharma Firms Went Bankrupt.– But Things Have Changed.
What Changed:– AIDS drugs.
– Health Care Budget Pressures.
– Growth in Developed Markets Slowed.
– Growth in Emerging Markets Grew.
©Arun Sharma, All Rights Reserved22
Big Pharma is a Laggard in Growth
Source: Vivian Hunt, Nigel Manson, and Paul Morgan (2011), "A wake‐up call for Big Pharma: Lower profit margins suggest a need for new business models,: McKinsey Quarterly, December.
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved23
Most of the Growth Has not Come from Big Pharmaceutical Model
Source: Vivian Hunt, Nigel Manson, and Paul Morgan (2011), "A wake‐up call for Big Pharma: Lower profit margins suggest a need for new business models,: McKinsey Quarterly, December.
© Arun Sharma, All Rights Reserved24
Competition Has Increased in the Pharmaceutical Industry
Source: Vivian Hunt, Nigel Manson, and Paul Morgan (2011), "A wake‐up call for Big Pharma: Lower profit margins suggest a need for new business models,: McKinsey Quarterly, December.
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved25
R&D Issues
– R&D Expenses went from $20B in 1999 to $70B in 2010.• Reduced Efficiency.
– Pfizer had 5,000 researchers and 2.7 million square feet of space in Connecticut and only one major drug was released –Chantix.
• Big R&D Departments Did Not Increase Innovation.– Bureaucracies emerged – small scientist groups were best at creating new drugs.
– Ideal size 20‐40 scientists.
• Blockbuster Drug (everybody can use) Opportunities are Fewer.– Smaller diseases are the focus (e.g., Alzheimer’s).
• FDA Trials are taking longer and are more contentious.
Source: http://online.wsj.com/article/SB10001424052970204466004577102151263615364.html
©Arun Sharma, All Rights Reserved26
Pharmaceutical Image Issues
Source: Pharma 2020: The Vision; PriceWaterhouseCoopers, www.pwc.com/pharma2020
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved27
General Health Care Trends
General.– Personalized Medicine.
– Reduction in Marketing.
Advanced Countries.– Management of Chronic Disease.
• Accounts for more than 20% of health care spending (McKinsey 2010).
• U.S. ‐‐ 5% of Population consumes 49% of spend; 50% consume 3% of spend(PWC 2020).
– Patient Pays More.
– Reduction in Administration.
Emerging Markets.– Local Competition.
– Government Pays More of Medical Expenses.
©Arun Sharma, All Rights Reserved28
Personalized Medicine
Source: Jerel Davis, Philip Ma, and Saumya Sutaria, The microeconomics of personalized medicine, McKinsey Quarterly, February 2010
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved29
Some Good News for European Pharma Firms(US Drug Approvals)
Source: “Overheard”, Wall Street Journal, August 18, 2013; http://online.wsj.com/article/SB10001424127887323455104579017111784720506.html
©Arun Sharma, All Rights Reserved30
Increased Focus on Prices in Markets
Countries have started increasing pressure on prices.– US ‐‐ increase pressure on prices (private insurers, Medicaid rebates).
– Japan, Spain, Italy, Canada, South Korea, France Germany Spain, Turkey and Greece all reduced reimbursement rates.
Emerging Nation Strategies.– China and India.
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved31
GENERICS
©Arun Sharma, All Rights Reserved32
Generic Market
Will Drive the Pharmaceutical Market.
Will Grow from $120 Billion in 2012 to $180 Billion in 2018.– 90% of the growth will come from Emerging Markets.
– From 37% of market share, developed countries will drop to 30% of world market share.
Source: Francisco Ballester, Sandoz
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved33
Generic Players
Source: Francisco Ballester, Sandoz
©Arun Sharma, All Rights Reserved34
Positioning
Source: Francisco Ballester, Sandoz
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved35
The Current Situation in Countries
Local Branded Generic Manufacturers Dominate Most Markets.– Global Pharma have become specialists/niche players.
The Battle of Generics has been won by locals in Emerging Markets.
Global Pharma wants to Attack Biosimilars.– Generic Versions of Biologics.
Big Pharma have Money and Expertise to Develop Biosimilars that Local Generic Manufacturers do (may) not have.
©Arun Sharma, All Rights Reserved36
Results ‐‐Local Generic Firms Dominate Emerging Markets (India) (2012 Sales in Billion Dollars)
Source: Drug Plan Draws Fire in India, May 21, 2013, WSJ; http://online.wsj.com/article/SB10001424052702303360504577411330099039816.html
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved37
BIOLOGICS
©Arun Sharma, All Rights Reserved38
Rise of Biologics
Source: Francisco Ballester, Sandoz
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved39
Biologics Race
Source: Roche Invests $877 Million to Boost Biologic Therapies Production; WSJ, October 14; http://online.wsj.com/news/articles/SB10001424052702303376904579134981048824064
©Arun Sharma, All Rights Reserved40
What Are Biosimilars?
Source: http://online.wsj.com/article/SB10001424127887323864304578318111144984632.html#project%3DBIOSIMILAR022613_pg%26articleTabs%3Dinteractive
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved41
Why Are They Important?
Sales of Biologics.
– Expected to be $175 Billion in 2013.– About one‐third will lose their patent protection in the next five
years.
– In Brazil, 3% of the drugs are biologics but they account for 40% of the budget.
Premium– Small molecules drop to 10% of patented prices.
– Biosimilars drop to 73% of patented prices currently and maximum expected is 50%.
Time to Market
– Small molecules: 1‐2 years.– Biosimilars: 7‐8 years.
©Arun Sharma, All Rights Reserved42
Biotechs Get Hot
Source: How Biotechs Got Hot, July 1, 2013, WSJ; http://online.wsj.com/article/SB10001424127887324251504578577541230012714.html
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved43
Will The Bio Similar Strategies Succeed?
Tremendous Competition.– India – Cipla, Intas, Dr. Reddy’s, Ranbaxy.
– China – Celltrion, Shanghai CP Goujian.
– Global – Teva, Merck, Samsung Biosimilar, Novartis (Sandoz), Amgen, Boehringer Ingelheim, Pfizer.
High Failure Rate.– Merck, Teva, Samsung, Novartis.
– Need Cell Development Expertise.
Big Pharma is contacting Emerging Market firms to help them do clinical testing – Merck and Dr. Reddy’s.
©Arun Sharma, All Rights Reserved44
EMERGING MARKETS
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved45
Developed Economies
2008 2009 2010 2011 2012 2013 2014World output 3 ‐0.7 5.3 3.9 3.2 2.9 3.6
Advanced economies
0.5 ‐3.7 3.2 1.7 1.5 1.2 2.0
United States 0.4 ‐3.5 3.0 1.8 2.8 1.6 2.6
Euro area 0.6 ‐4.3 1.9 1.5 –0.6 –0.4 1.0
Germany 1.2 ‐5.1 3.6 3.4 0.9 0.5 1.4
France 0.3 ‐2.6 1.4 2.0 0 0.2 1.0
Italy ‐1 ‐5.2 1.5 0.4 –2.4 –1.8 0.7
Spain 0.9 ‐3.7 ‐0.1 0.1 –1.6 –1.3 0.2
Japan ‐1.2 ‐6.3 4.4 –0.6 2.0 2.0 1.2
United Kingdom 0.5 ‐4.9 2.1 1.1 0.2 1.4 1.9
Canada 0.4 ‐2.8 3.2 2.5 1.7 1.6 2.2
Other advanced economies
1.7 ‐1.1 5.8 3.2 1.9 2.3 3.1
Source: IMF World Economic Outlook Update, September 2011; January 2012; July 2012, April 2013
©Arun Sharma, All Rights Reserved46
Developing Economies Growth Rates
Area 2008 2009 2010 2011 2012 2013 2014
World output 3 ‐0.7 5.2 3.9 3.2 2.9 3.6
Advanced economies 0.5 ‐3.7 3.2 1.7 1.5 1.2 2.0
Emerging and developing economies 6.1 2.8 7.5 6.2 4.9 4.5 5.1
Central and Eastern Europe 3.1 ‐3.6 4.5 5.4 1.4 2.3 2.7
Commonwealth of Independent States 5.5 ‐6.4 4.8 4.8 3.4 2.1 3.4
Russia 5.6 ‐7.8 4.3 4.3 3.4 1.5 3.0
China 9.6 9.2 10.4 9.3 7.7 7.6 7.3
India 7.3 6.8 10.6 6.3 3.2 3.8 5.1Indonesia, Philippines, Malaysia, Thailand and Vietnam 4.7 1.7 7.0 4.5 6.2 5.0 5.4
Middle East and North Africa 5.3 2.6 4.9 3.9 4.6 2.3 3.6
Latin America and the Caribbean 4.3 ‐1.8 6.2 4.6 2.9 2.7 3.1
Brazil 5.1 ‐0.6 7.5 2.7 0.9 2.5 2.5
Mexico 1.3 ‐6.1 5.5 4.0 3.6 1.2 3.0
Source: IMF World Economic Outlook Update, September 2011; January 2012; July 2012, April 2013, October 2013
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved47
Emerging Markets (Billion Dollars)
Source: Drug Plan Draws Fire in India, May 21, 2013, WSJ; http://online.wsj.com/article/SB10001424052702303360504577411330099039816.html
©Arun Sharma, All Rights Reserved48
Western Pharmaceutical Firms and Emerging MarketsEmerging markets are facing increased price pressures due to reduction in pricing power, regulatory intervention, and lower priced “good enough” products. – “Advanced market” strategy has worked well for the high end markets; emerging market mass markets will require a complete rethink. • Emerging market competitors will always have cost structures that are lower than Western firms.
• The asymmetric effects of ethical codes – Western firms have them and Emerging market competitors do not.
• So how do Western firms battle with our emerging market competitors?
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved49
How Did Western Firms Compete in Emerging Markets?Followed Advanced Country Model.– Attempted to Enforce Patent Laws.
– Multinationals Buy Local Firms.• Sanofi‐Aventis buys Medley (Brazil).
– Pfizer buys 40% of Teuto (Brazil).
• Daiichi Sankyo buys Ranbaxy Labs (India).
• Abbott Buys Piramal in India.
– Multinationals Use Local Firms as R&D partners.• Lilly uses Jubiliant and Piramal (India) for faster R&D.
Problems of Growth – Market Mismatch.– Different markets ‐‐ different needs.
©Arun Sharma, All Rights Reserved50
China
China investigates baby formula firms for pricing violations in 2013.– Nestlé SA, Danone SA, Royal FrieslandCampina NV, Abbott Laboratories and Mead Johnson Nutrition.
– All firms under investigation reduce baby formula prices.
Other Industries– Pharma, Medical Devices, TVs, Automobiles.
Source: China Investigates Foreign Makers of Baby Formula, July 2, 2013, WSJ; http://online.wsj.com/article/SB10001424127887323297504578580920868011296.html; http://online.wsj.com/article/SB10001424127887323455104579012543957866998.html
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved51
China ‐‐ Pharmaceutical
China Investigates Pharmaceutical Industry in 2013.– 27 Firm on Cost Issues– 33 Firms on Pricing Issues
• GlaxoSmithKline, Merck, Astellas, Sandoz, Boehringer Ingelheim, Baxter International and Fresenius.
– Pharma companies on compliance business practices (GSK, UCB and others).
– GSK employees were charged with bribery. • GSK promised to reduce pharmaceutical prices.• Xinhua states “China may see a nationwide price cut on medicines).
One Target may be the 500 National Essential Drug List where Big Pharma Seek Premiums.
Source: Pharma Can Survive China's War on Drugs, July 5, 2013, WSJ; http://online.wsj.com/article/SB10001424127887324260204578587372019648796.html
©Arun Sharma, All Rights Reserved52
India
In November 2012, India's Intellectual Property Appellate Board a blow by revoking the patent on Roche’s Pegasys (Hepatitis C drug).– Roche announced plans to reduce costs of two cancer drugs, Herceptin and Mabthera in 2013, without any requests from the Indian government.
Indian Government won a case against Novartis for Glivec. The courts said that pharmaceutical companies had to prove significant clinical efficacy enhancements of their drugs over already‐patented compounds.
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved53
India
In 2012, India’s patent office forced Bayer AG to grant a license to an Indian generic‐drug producer for Nexavar (kidney‐ and liver‐cancer medicine) for patient health and affordability reasons. – In response, Cipla reduced prices of cancer medicine by 75% and is selling generic versions of patented Bayer, Novartis and AstraZeneca cancer drugs in India and other developing countries.
More Price Controls are Coming.
©Arun Sharma, All Rights Reserved54
Indian Government’s New Price Control Policy (2012)
Source: Drug Plan Draws Fire in India, May 21, 2012, WSJ; http://online.wsj.com/article/SB10001424052702303360504577411330099039816.html
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved55
Implication from China and India
Traditionally, firms would withdraw drugs from the emerging market when faced with regulatory price pressures. The actions of firms suggest that emerging markets are too large to ignore and firms are willing to reduce prices dramatically.
Local firms are willing to create generic versions of pharmaceuticals.
Other large emerging nations would want to follow the same policy. If China and India succeed, will other emerging nations follow?
©Arun Sharma, All Rights Reserved56
Industry Trends Latin America
Highest Growth Countries (worldwide):– Venezuela, Argentina, China, Ukraine, Vietnam, India and Brazil.• 2015 Size – China #3; Brazil #6; India #8; Mexico # 14; Venezuela #15 in the World.
Latin American Market Estimate for 2012– $70 Billion; Brazil is 40% of the Market; Mexico 20%.
Affluent and Aging Population.
Growth in Government and Private Insurance.– Pharmaceutical Coverage is Low in Latin America.
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved57
Industry Trends Latin America
High Price Sensitivity– But also Brand and Relationship Sensitive.
Competition– Local Firms Will Dominate (2,000 firms in LAC).
• Government Relationships, Provider Relationships, Distribution Channel Relationships, Low Prices– Big Pharma Will Need Partners (Government, Local Firms).
– Value Focus will be needed.
– Innovation Will Not be a Differentiator.
– Need to Reduce Costs
– Enhance Brand and Relationships. LatinAmerica
©Arun Sharma, All Rights Reserved58
Did it Work? Shift in Brazilian Markets ‐‐ 1998 to 2007
FirmsCountry of Origin
Market Share (1998) in percentage
FirmsCountry of Origin
Market Share (2007) in percentage
Novartis Switzerland 6.30 EMS Sigma Pharma Brazil 7.10
Roche Switzerland 5.50Sanofi – Aventis (bought Medley)
France 6.40
Bristol‐Meyers Squibb
USA 5.40 Ache Brazil 5.60
Hoechst Marion Roussel
Germany 5.20 Medley Brazil 5.50
Ache/Prodome Brazil 4.70 Novartis Switzerland 4.40
Janssen Cilag Belgium 3.70 Eurofarma Brazil 3.50
Boehringer Ing. Germany 3.70Pfizer(bought Teuto)
USA 3.40
Glaxo WellcomeUnited Kingdom
3.50Bayer Schering Plough
Germany 3.20
Schering Plough Germany 3.20 Boehringer Ing. Germany 2.60
Eli Lilly USA 3.00 Nycomed Denmark 2.40
Demais Empresas ‐ 55.80 Demais Empresas ‐ 55.90
Source: Caliari and Ruiz (2010), “Structure and Innovation in Pharmaceutical Industry in Brazil: The impact of Generic Drugs;” http://www2.druid.dk/conferences/viewpaper.php?id=500557&cf=44
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved59
TWO TRACK COMPETITION
©Arun Sharma, All Rights Reserved60
Two Track Competition
Developing Nation FirmsTraditional Pharmaceutical Firms
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved61
Patent Cliff Issues: BMS
Bristol‐Myers‐Squibb sold off its baby formula, ultrasound machines and surgical bandages businesses.
The company has a third fewer employees, and half as many manufacturing plants as it did in 2006.
Midsize Player Looking for Big Deal (e.g., Biogen Idec, Shire, Gilead Sciences).
Source: “Bristol-Myers Stalks Deals To Bolster Its Drug Lineup”, Wall Street Journal, March 4, 2013; http://online.wsj.com/article/SB10001424127887323293704578332191493675744.html
©Arun Sharma, All Rights Reserved62
New Shifts ‐‐ Abbott
Abbott Has Split into Two Firms:– Abbott has created a company focused on diversified medical
products consisting of medical devices, established generic pharmaceuticals, diagnostic and nutritional businesses. This company, has retained the Abbott name, has sales of approximately $22 billion and is led by Abbott CEO Miles White.
– The second company Abbvie, with current sales of around $18 billion, has taken over Abbott's research‐based drug business an pipeline focused on specialty markets such as multiple sclerosis, immunology and hepatitis C. The research company's drug roster include Abbott's biologic, or biotech drugs, including the rheumatoid arthritis blockbuster Humira.
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved63
SCENARIO PLANNING FOR PHARMACEUTICAL MARKET
©Arun Sharma, All Rights Reserved64
Scenario Planning
What are the 3‐4 Most Probable Business Scenarios in our Markets?
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved65
30 Minute Workshop
©Arun Sharma, All Rights Reserved66
Worksheet
Trends– List them.
Scenarios (1‐2)– Details (Describe them).
Compliance Function Shifts.– 3‐4 per Scenario.
Summarize Findings.
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved67
COMPLIANCE STRATEGY
©Arun Sharma, All Rights Reserved68
Compliance Related Trends in the Pharmaceutical IndustryTraditional Focus on Sales, Commercial, Physician and Medical Professionals is Declining.– Channels, Alliances and Institutions.
From Internal Sourcing to External Sourcing.– Collaboration
– R&D, Manufacturing, Distribution.– Outsourcing internal functions.
Risk increases exponentially with partners/ outsourcing firms.– Increase knowledge of risk management.
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved69
Our Research Objectives
How to Enhance the Efficiency and Effectiveness of the Compliance Organization and Function in Emerging Markets.
Conducted interviews with:– External Stakeholders – Medical Professionals, Associations, Hospital Executives, Insurance Firm and Governments Ministry Heads.
– Internal Stakeholders ‐‐Western Firms executives
©Arun Sharma, All Rights Reserved70
External Stakeholders Results
High/Low Price Sensitivity– But also Brand and Relationship Sensitive.
Competition– Local Firms Will Dominate (5,000 firms in Emerging Markets).• Government Relationships, Provider Relationships, Distribution Channel Relationships, Low Prices– Big Pharma Will Need Partners (Government, Local Firms).
– Value Focus will be needed.
– Innovation Will Not be a Differentiator.
– Need to Reduce Costs
– Enhance Brand and Relationships.
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved71
External Stakeholders Results ‐‐ Issues Facing RespondentsTwo Tier Market
• Small High End, Large Middle/low end.
Demand for Effective Health Programs Growing.
Health Care is expensive and Rapidly Rising.• Most countries are increasing health care spending for citizens:
– Expectations rising faster than affordability.
Need for Better Health Care Practices.
– Training of Doctors, Nurses and Administrators.
Doctors feel that they do not have enough of current knowledge:
• Need Assistance.
©Arun Sharma, All Rights Reserved72
External Stakeholders Results ‐‐ Best Practices
Thought Leadership.
Provide Assistance in Health Management.– Disease Prevention and Management.
Cutting‐edge Medicine and Technology.
Build Clinics.
Train Doctors and Nurses.
Free Medicine.
Develop drugs for critical needs (e.g., malaria).
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved73
Internal Stakeholders Results – Compliance PoliciesCompliance function is concentrated on enforcing policy rather than enhancing business.
Commercial/marketing feel high constraints from legal and compliance departments.
Doctors do not choose pharmaceutical products based on ethical considerations, but rather on efficacy and value.
The emphasis on value (versus Efficacy) is increasing.
©Arun Sharma, All Rights Reserved74
Internal Stakeholders Results – Compliance Function‘’No’’ is always a Less Risky Options ‘’Yes.’’
Commercial/Marketing feels that Compliance Rules are too Restrictive and do not Allow them to Practice their Functions well.
Cooperation between Compliance and Commercial is not ideal.
Some Pharmaceutical Firm’s Compliance Policies are Stricter than Competition.
The Compliance Function does not have adequate Understanding of the Business.
Compliance Policies have Restricted Brand Enhancing Activities.
Medical Professionals are not Getting the Medical/Scientific Information that they need.
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved75
Pharmaceutical Firm Operational Excellence 2005
Future Revenue
Current Revenue
Generators
Revenue Accelerators
Cost Containment
Ethical Boundary
2005
Ethical Boundary
2013
©Arun Sharma, All Rights Reserved76
Pharmaceutical Firm Operations 2013
Future Revenue
Current Revenue
Generators
Revenue Accelerators
Cost Containment
Ethical Boundary
2005
Ethical Boundary
2013
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved77
Compliance Role – Let Nobody Go Into the Box
Compliance Rules and Regulations
©Arun Sharma, All Rights Reserved78
Compliance Role Shift – To Reduce Risk, The Size of the Box Is Increased
Compliance Rules and Regulations
Buffer Zone
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved79
Compliance Function Issues
Control Function.– Strategic?
– Involved in Market Strategy Planning?
Understanding of Business?
Programmed to Say NO.
What Happens to Functions that are Control Functions and not Strategic?– They Get Outsourced.
• IRB, IT, Banking Risk Management, HR.
©Arun Sharma, All Rights Reserved80
Emerging Compliance Issues – Moving Toward Compliance 2.0Different Compliance Requirements for Different Firms– Advanced Country Firms and Emerging Country Firms.
Multichannel Partners.
Direct to Patient by Firm and Distribution.
Patient Level Compliance.– Adherence, Promotion, Prevention.
Digital Compliance.
Standardized Compliance Programs– Rise of Third Party Compliance Certifiers.
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved81
Compliance 2.0
An Adviser function.
– Says more yes’s that no’s.
Objectives versus Behaviors.
Planning with Commercial and Marketing Function.
– Enhance Brand.
Creative and Innovative.
– Grow within the Letter of the Law.
Role.
– Seen by Firm as a key Supporter.
Focus.
– More External than Internal. Compliance 2.0
©Arun Sharma, All Rights Reserved82
Compliance 2.0‐‐ The Journey
PartnershipCollaboration
Compliance Insight
Control
Market Insight
Compliance Knowledge
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved83
Strategic Compliance Role – Bring Practices as Close to the Box As Possible
Compliance Rules and Regulations
©Arun Sharma, All Rights Reserved84
Group Workshop Process
© Arun Sharma, All Rights Reserved
©Arun Sharma, All Rights Reserved85
Summary
Fundamental Shifts in Markets– Branded versus Generic
– Advanced Markets versus Developing Markets
– Best versus “good enough.”
Compliance Needs to be More Strategic.
©Arun Sharma, All Rights Reserved86
Arun Sharma
Dr. Arun Sharma is Executive Director of the JAE Leadership Institute and Professor in the Marketing Department at the School of Business Administration, University of Miami. Arun has extensive knowledge of firms through his experience in consulting, and conducting seminars. He is a well known expert in Global Market Trends, Leadership Strategies, Sustainable Competitive Strategies, and Market Strategy and his expertise is in designing and implementing corporate strategies. He has consulted and conducted seminars for companies such as Accenture, Agilent Technologies, Ambrosetti, American Express, AT&T, Bell South, Citrix, Ericcson, Exxon, Goodyear, HP, IBM, Lucent, Macy’s, MasterCard, Motorola, Siemens, Sprint, Telecom Italia, Telecom Italia Mobil, Visa International, Wal‐Mart and Western Union. He has extensive expertise in business and consumer markets, technology, financial, telecommunication, healthcare, consumer goods and consulting industries.
He has previously taught at the University of Illinois at Urbana‐Champaign where he received his Ph.D. in marketing in 1988. Arun also has an MBA and a Bachelor of Engineering degree in Metallurgy. Prior to joining the academic world, he worked for three years in a high‐technology firm where he handled product management and sales management responsibilities.
Arun has published extensively (over 80 refereed articles) and is on the review board of major journals and has received many excellence in research and excellence in teaching awards from the School of Business Administration at the University of Miami. He can be contacted at 305.284.1770, Fax: 305.667.2557 and email: asharma@bus.miami.edu.